Analyst Price Targets — PSTV
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 23, 2026 11:05 am | Sean Lee | H.C. Wainwright | $25.00 | $7.13 | TheFly | Plus Therapeutics price target lowered to $1 from $2 at H.C. Wainwright |
| November 26, 2025 12:48 pm | Sean Lee | H.C. Wainwright | $50.00 | $15.22 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Plus Therapeutics Inc. (PSTV) |
Latest News for PSTV
Expands access by 6 million covered lives, advancing commercial momentum for CNSide® in metastatic CNS cancers Expands access by 6 million covered lives, advancing commercial momentum for CNSide® in metastatic CNS cancers
HOUSTON, April 23, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announced today the initiation of manufacturing activities and technology transfer with SpectronRx under a previously executed Master Services Agreement (MSA), in…
HOUSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that it has granted inducement awards to Eric J Daniels, M.D., its new Chief Development Officer who joined the Company on April 20, 2026.
HOUSTON, April 21, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announced that it has received notification from The Nasdaq Stock Market LLC (“Nasdaq”) confirming the Company has regained compliance with the minimum bid price…
Health economics and reimbursement expert brings over two decades of experience in payer strategy, value-based pricing, and health policy supporting CNSide adoption and long-term commercialization strategy for REYOBIQ™ Health economics and reimbursement expert brings over two decades of experience in payer strategy, value-based pricing, and health policy supporting CNSide adoption and long-term commercialization…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PSTV.
U.S. House Trading
No House trades found for PSTV.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.